Latest From Biotech Now

Here are the Facts about the IPR Kill Rate


FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the rapidly increasing number of biopharma related inter partes reviews (IPR) currently within the United States Patent and Trademark Office (PTO). It is troubling that in a single breath Ronny Gal both dismissed the biopharmaceutical industry’s concerns with the PTO’s IPR process and acknowledged that limited data prevents any firm conclusions about the potential impact of IPR on biotech innovation. If Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Statement: Institute for Clinical and Economic Review Framework


This week, the Institute for Clinical and Economic Review (ICER) released its Value Assessment Framework. While we welcome a robust discussion on the value of treatments and cures, we have concerns with ICER’s methodology, which has not been validated, and preliminary conclusions which underestimate the value of innovative new medicines. We believe that the most important priority is to empower patients with information that will be helpful in clinical decision-making with their healthcare providers, and Read More >

Health  |  Leave a comment  |  Email This Post

Health Affairs Study: Want to save money in Medicaid? Increase adherence.

Health Affairs

At BIO, we have long argued that the use of prescription medicines can yield substantial savings to other areas of the healthcare system by reducing costly hospitalizations, surgeries, visits to the emergency room and other non-drug drivers of health spending. A study published in Health Affairs this week further bolstered that point and quantified the potential savings that Medicaid could realize from better prescription drug adherence among beneficiaries. The authors found that increasing the number Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Ag Groups Push China’s President Xi Jinping on Biotech

Xi Jinping, October 2013 Wikipedia

The U.S. agriculture sector is urging President Barack Obama to pressure China’s President Xi Jinping to improve his country’s biotech approval process when the two meet later this September, Politico Pro Ag’s Bill Tomson recently reported. BIO along 100 signatories signed on to the September 4th letter to the White House, encouraging the president to squeeze biotech into the agenda. According to Tomson, Obama already engaged Xi on China’s unreliable approval process in November during the Asia-Pacific Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

102 Organizations Urge Congress to Maintain a Strong Patent System and Protect Innovation

US Capitol Building

A diverse group of more than 100 national and state-based advocacy organizations have united to urge Congress to preserve important patent protections that incentivize biopharmaceutical research necessary to innovate and develop new cures and treatments for serious diseases. In a letter sent to the Hill this week, these patient advocates asked Congress to amend the Innovation Act (H.R. 9) to preserve the highly-detailed and sophisticated systems designed by Hatch-Waxman and BPCIA and avoid weakening the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,